Blood test for identifying marker of Alzheimer's disease

Media Coverage
Written By

At the Alzheimer's Association International Conference, July 2017, Dr. Randall Bateman presented data showing that amyloid beta (Abeta) concentrations can be measured reliably using mass spectrometry, and that the ratio between two of the Abeta isoforms measured in plasma can be used to indicate if a person has brain amyloidosis - a hallmark pathology observed in patients with Alzheimer's disease.Alzforum Coverage

Washington University School of Medicine Press Release

Alzheimer's Association Press Release

 

Previous

ADDF Announces Major Funding Commitment to Validate an Amyloid Blood Test for Non-Invasive Early Detection of Alzheimer's
Next

NIH Blog: NIH Director Highlights Tau Diagnostic Technology